Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

Table 1 Data and assumptions used for the base case analysis (using estimated average values) and for sensitivity analyses

	Base case		Low cost scenario		High cost scenario
Probabilities
Incidence of clinically suspected HSR	10.0%	EPI-001 + PREDICT-1 [14, 27]	7.8%	PREDICT-1 [14]	12%	[28]
Prevalence of HLA-B*5701	7.3%	EPI-001 [27]	5.6%	PREDICT-1 [14]	9.5%	EPI-001 (Eastern Europe ethnicity) [27]
Negative predictive value of genetic HLA-B*5701 test	99.5%	assumption	99%	assumption	100%	PREDICT-1 [14]
Hospitalization rate	12.0%	unpublished data¹	10%	unpublished data¹	15%	unpublished data¹
Private health insurance rates	15%	5C study + single centre evaluation	10%	private health insurance rate in total population in Germany [30]	20%	private health insurance rate in HIV-infected population in Germany [30]
Percentage of antiretroviral medication (ABC/3TC FDC) being discarded	53.7%	5C study	50%	assumption	56.2%	PREDICT-1 [14]
Costs
Costs of HLA-B*5701-screening	€86	assumption	€108	assumption	€64	assumption
Costs of a monthly pack of ABC/3TC	€758	Lauertaxe [38]	NA		NA
Concomitant medication	€20	5C study	*	*	*
Costs for outpatient care	€73	5C study	*	*	*
Hospital costs for cases receiving inpatient care	€6,904	5C study	€4,623	5C study: lump sum for standard inpatient care (DRG-Code S63B)	€8,436	5C study: mean hospital costs in 5-centre study when excluding hospital stays of only one day
Extra charge for patients with private health insurance	€1,884	5C study	NA		NA
Indirect costs	€873	MICE module [23, 31–33]	€0		NA

* Due to only minimal impact on cost outcomes, no sensitivity analyses performed; NA = not available
¹GSK studies, data on file

ISSN: 2047-783X